 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...464465466467468469470471472473474...522523» |
- || Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: NCI-2015-00960: Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 14, 2018
P2, N=131, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2021 --> Jun 2022
- | Trial completion date, Trial primary completion date, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Mar 13, 2018
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2021 --> Jun 2022 Trial completion date: Jun 2019 --> Jul 2020 | Trial primary completion date: Jun 2018 --> Jul 2019
- | Tecentriq (atezolizumab) / Roche
New P2 trial: HOVON 151: The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (clinicaltrials.gov) - Mar 12, 2018
P2, N=114, Not yet recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- | Phase classification, Metastases: Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer (clinicaltrials.gov) - Mar 12, 2018
P1, N=15, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jun 2019 --> Jul 2020 | Trial primary completion date: Jun 2018 --> Jul 2019 Phase classification: P=N/A --> P1
- | Rituxan (rituximab) / Roche
Trial completion, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Mar 12, 2018
P1/2, N=50, Completed, Sponsor: Lund University Hospital
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed
- || Tazverik (tazemetostat) / Eisai, Ipsen, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: Epi-RCHOP: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (clinicaltrials.gov) - Mar 12, 2018
P1/2, N=133, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Active, not recruiting --> Completed Trial completion date: Jan 2020 --> May 2023 | Trial primary completion date: Dec 2017 --> Sep 2020
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Trial initiation date: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Mar 12, 2018
P3, N=774, Not yet recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jan 2020 --> May 2023 | Trial primary completion date: Dec 2017 --> Sep 2020 Initiation date: Dec 2017 --> Apr 2018
- |||| Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy: SELENE : A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 9, 2018
P3, N=403, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Dec 2017 --> Apr 2018 Trial primary completion date: Nov 2018 --> Jul 2019
- | Phase classification, Trial completion date, Trial primary completion date: COC-IDCB: A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (clinicaltrials.gov) - Mar 9, 2018
P1, N=300, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Nov 2018 --> Jul 2019 Phase classification: P1/2 --> P1 | Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2017 --> Dec 2019
- lacnotuzumab (MCS110) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer (clinicaltrials.gov) - Mar 8, 2018
P1, N=27, Not yet recruiting, Sponsor: Washington University School of Medicine
Phase classification: P1/2 --> P1 | Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2017 --> Dec 2019 Trial completion date: Jul 2020 --> Sep 2020 | Initiation date: Feb 2018 --> Apr 2018 | Trial primary completion date: Mar 2019 --> May 2019
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, Trial completion date, Trial termination, Trial primary completion date: GAINED: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Mar 7, 2018
P3, N=671, Terminated, Sponsor: The Lymphoma Academic Research Organisation
Trial completion date: Jul 2020 --> Sep 2020 | Initiation date: Feb 2018 --> Apr 2018 | Trial primary completion date: Mar 2019 --> May 2019 Trial completion date: Feb 2019 --> Dec 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Aug 2016; experimental treatment not Superior to standard - no need to continue the follow-up
- Lartruvo (olaratumab) / Eli Lilly
Enrollment closed, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 7, 2018
P1b, N=40, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Feb 2019 --> Dec 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Aug 2016; experimental treatment not Superior to standard - no need to continue the follow-up Recruiting --> Active, not recruiting
- | entospletinib (GS-9973) / Kronos Bio, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy (clinicaltrials.gov) - Mar 7, 2018
P1/2, N=131, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> Jun 2018
- | Trial completion date, Trial primary completion date: PVAB: Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin (clinicaltrials.gov) - Mar 6, 2018
P2, N=90, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Trial primary completion date: Jan 2018 --> Jun 2018 Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jan 2018 --> Dec 2018
- | cisplatin / Generic mfg.
Trial completion date, Trial primary completion date: PARROT: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor (clinicaltrials.gov) - Mar 6, 2018
P1/2, N=50, Recruiting, Sponsor: Catholic University of the Sacred Heart
Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jan 2018 --> Dec 2018 Trial completion date: Jan 2018 --> Oct 2018 | Trial primary completion date: Jan 2018 --> Apr 2018
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Trial initiation date: Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (clinicaltrials.gov) - Mar 6, 2018
P2, N=400, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jan 2018 --> Oct 2018 | Trial primary completion date: Jan 2018 --> Apr 2018 Initiation date: Feb 2018 --> Mar 2018
- ||| Darzalex (daratumumab) / J&J
Trial initiation date: DELPHINUS: A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 3, 2018
P2, N=69, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Feb 2018 --> Mar 2018 Initiation date: Apr 2018 --> Apr 2018
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial initiation date: LCCC1637: BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma (clinicaltrials.gov) - Mar 3, 2018
P2, N=28, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Apr 2018 --> Apr 2018 Initiation date: Jan 2018 --> Mar 2018
- || Vectibix (panitumumab) / Amgen
Trial completion date: Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer (clinicaltrials.gov) - Mar 3, 2018
P2, N=72, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jan 2018 --> Mar 2018 Trial completion date: Oct 2023 --> Oct 2024
- || Arzerra (ofatumumab) / Novartis, Genmab
Trial completion date, Combination therapy: Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 3, 2018
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2023 --> Oct 2024 Trial completion date: Jul 2019 --> Jul 2020
- | Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion date, Trial primary completion date: Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma (clinicaltrials.gov) - Mar 2, 2018
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jul 2019 --> Jul 2020 Trial primary completion date: Feb 2018 --> Feb 2019 | Trial completion date: Feb 2018 --> Feb 2019
- | Herceptin (trastuzumab) / Roche
Trial completion, Trial primary completion date: Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer (clinicaltrials.gov) - Mar 2, 2018
P2, N=48, Completed, Sponsor: Rita Sanghvi, Mehta
Trial primary completion date: Feb 2018 --> Feb 2019 | Trial completion date: Feb 2018 --> Feb 2019 Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Mar 2011
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Biomarker, Phase classification, Enrollment change, Trial termination: Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=23, Terminated, Sponsor: Indiana University School of Medicine
Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Mar 2011 Phase classification: P4 --> P=N/A | N=60 --> 23 | Active, not recruiting --> Terminated; This study has been difficult to recruit.
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open, Trial initiation date: AKY15-HK-301_NEPA Study (clinicaltrials.gov) - Mar 2, 2018
P2, N=60, Recruiting, Sponsor: Chinese University of Hong Kong
Phase classification: P4 --> P=N/A | N=60 --> 23 | Active, not recruiting --> Terminated; This study has been difficult to recruit. Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018
- | Decadron (dexamethasone) / Merck (MSD)
Trial completion date, Trial primary completion date: Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (clinicaltrials.gov) - Mar 1, 2018
P2, N=41, Active, not recruiting, Sponsor: Yogesh Jethava
Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018 Trial primary completion date: Jun 2018 --> Jun 2020 | Trial completion date: Dec 2018 --> Dec 2020
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: IELSG30: Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (clinicaltrials.gov) - Feb 28, 2018
P2, N=35, Recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Trial primary completion date: Jun 2018 --> Jun 2020 | Trial completion date: Dec 2018 --> Dec 2020 Trial primary completion date: Dec 2017 --> Jul 2017
- | Epratucyn (epratuzumab) / Gilead
Trial completion, IO biomarker: CHEPRALL: Multi-centric Study (clinicaltrials.gov) - Feb 27, 2018
P2, N=57, Completed, Sponsor: Nantes University Hospital
Trial primary completion date: Dec 2017 --> Jul 2017 Recruiting --> Completed
- |||| Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: POLARIX: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 27, 2018
P3, N=875, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Trial primary completion date: Jan 2021 --> Dec 2019 | Trial completion date: Oct 2023 --> May 2023
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer (clinicaltrials.gov) - Feb 26, 2018
P2, N=27, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jan 2021 --> Dec 2019 | Trial completion date: Oct 2023 --> May 2023 Trial primary completion date: Jun 2018 --> Jun 2019 | Trial completion date: Jun 2018 --> Jun 2019
- || Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date, Trial primary completion date: Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (clinicaltrials.gov) - Feb 26, 2018
P=N/A, N=117, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2018 --> Jun 2019 | Trial completion date: Jun 2018 --> Jun 2019 Trial primary completion date: May 2018 --> May 2019 | Trial completion date: May 2018 --> May 2019
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer (clinicaltrials.gov) - Feb 26, 2018
P1, N=30, Recruiting, Sponsor: Yale University
Trial primary completion date: May 2018 --> May 2019 | Trial completion date: May 2018 --> May 2019 Trial primary completion date: Dec 2017 --> Jul 2018 | Trial completion date: Feb 2018 --> Aug 2018
- | Ryzneuta (efbemalenograstim alpha) / Yifan Pharma
Trial completion: A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy (clinicaltrials.gov) - Feb 23, 2018
P1/2, N=15, Completed, Sponsor: Generon (Shanghai) Corporation Ltd.
Trial primary completion date: Dec 2017 --> Jul 2018 | Trial completion date: Feb 2018 --> Aug 2018 Recruiting --> Completed
- | propranolol / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Use of Propranolol Hydrochloride in the Treatment of Metastatic STS (clinicaltrials.gov) - Feb 23, 2018
P2, N=50, Not yet recruiting, Sponsor: Ain Shams University
Recruiting --> Completed Initiation date: Aug 2017 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2020 | Trial completion date: Aug 2019 --> Aug 2021
- | goserelin acetate / Generic mfg.
New P2 trial: NeoGONT: Neoadjuvant Goserelin for Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 23, 2018
P2, N=180, Not yet recruiting, Sponsor: Kasr El Aini Hospital
- | thioguanine / Generic mfg.
Trial completion, Trial completion date: LAL1308: Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=30, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Initiation date: Aug 2017 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2020 | Trial completion date: Aug 2019 --> Aug 2021 Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Jan 2018
- | Enrollment change: SPRING: High-Risk Neuroblastoma Chemotherapy Without G-CSF (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=13, Recruiting, Sponsor: Baylor College of Medicine
Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Jan 2018 N=21 --> 13
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion: Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma (clinicaltrials.gov) - Feb 20, 2018
P2, N=34, Completed, Sponsor: Massachusetts General Hospital
N=21 --> 13 Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Phase classification, Gene therapy: Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 20, 2018
P1, N=10, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Phase classification: P=N/A --> P1
- | Herceptin (trastuzumab) / Roche
Trial completion, Enrollment change, Adverse events: Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab (clinicaltrials.gov) - Feb 19, 2018
P=N/A, N=133, Completed, Sponsor: Vanderbilt University
Phase classification: P=N/A --> P1 Recruiting --> Completed | N=200 --> 133
- | Trial initiation date: URANUS: Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (clinicaltrials.gov) - Feb 19, 2018
P2, N=210, Not yet recruiting, Sponsor: The European Uro-Oncology Group
Recruiting --> Completed | N=200 --> 133 Initiation date: Oct 2017 --> Feb 2018
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial suspension, PD(L)-1 Biomarker, Surgery: Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer (clinicaltrials.gov) - Feb 19, 2018
P2, N=25, Suspended, Sponsor: Mayo Clinic
Initiation date: Oct 2017 --> Feb 2018 Recruiting --> Suspended
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Lartruvo (olaratumab) / Eli Lilly
New P1 trial, Combination therapy, Metastases: Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma (clinicaltrials.gov) - Feb 19, 2018
P1, N=30, Not yet recruiting, Sponsor: Marilyn Huang
- Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 13, 2018
P2, N=45, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Suspended Trial primary completion date: Dec 2018 --> Dec 2019 | Trial completion date: Dec 2018 --> Dec 2019
- | Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Feb 12, 2018
P2, N=105, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Dec 2018 --> Dec 2019 | Trial completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Feb 2018 --> Jan 2019 | Trial completion date: Feb 2018 --> Jan 2019
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker: NCI-2017-01718: Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma (clinicaltrials.gov) - Feb 12, 2018
P2, N=30, Not yet recruiting, Sponsor: University of Washington
Trial primary completion date: Feb 2018 --> Jan 2019 | Trial completion date: Feb 2018 --> Jan 2019 Initiation date: Jan 2018 --> May 2018 | Trial primary completion date: Feb 2020 --> Jun 2020 | Trial completion date: Feb 2020 --> Jun 2020
- | Trial completion date, Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 9, 2018
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Jan 2018 --> May 2018 | Trial primary completion date: Feb 2020 --> Jun 2020 | Trial completion date: Feb 2020 --> Jun 2020 Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
- | Trial completion date, Trial primary completion date, Metastases: Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer (clinicaltrials.gov) - Feb 9, 2018
P=N/A, N=15, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Jan 2018 --> Jan 2019
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial completion date: Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 9, 2018
P2, N=100, Completed, Sponsor: Fondazione Italiana Linfomi ONLUS
Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Jan 2018 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Apr 2017
- | Lonquex (lipegfilgrastim biosimilar) / Teva
Trial completion, Trial completion date, Trial primary completion date: Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer (clinicaltrials.gov) - Feb 9, 2018
P=N/A, N=40, Completed, Sponsor: Beaumont Hospital
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Apr 2017 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2018 | Trial completion date: Jul 2017 --> Feb 2018
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: HD0801: High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients (clinicaltrials.gov) - Feb 8, 2018
P2/3, N=520, Completed, Sponsor: Fondazione Italiana Linfomi ONLUS
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2018 | Trial completion date: Jul 2017 --> Feb 2018 Active, not recruiting --> Completed